New Publication: Medical Outcomes, Quality of Life, and Family Perceptions for Outpatient vs Inpatient Neutropenia Management After Chemotherapy for Pediatric Acute Myeloid Leukemia. Getz, et. al

Medical Outcomes, Quality of Life, and Family Perceptions for Outpatient vs Inpatient Neutropenia Management After Chemotherapy for Pediatric Acute Myeloid Leukemia

Kelly D. Getz, PhD; Julia E. Szymczak, PhD; Yimei Li, PhD; et al

Key Points

Question  What are the clinical outcomes and patient and family experiences associated with outpatient neutropenia management after intensive chemotherapy for pediatric acute myeloid leukemia (AML) compared with inpatient management?

Findings  In this cohort study including as many as 554 pediatric patients, patients discharged to outpatient management during neutropenia did not experience higher bacteremia incidence, delays to subsequent courses, or worse health-related quality of life compared with those who received inpatient management. Most patients and families were satisfied with the discharge practice offered by the treating institution, but experiences varied, suggesting that outpatient management may not be appropriate for all families.

Meaning  These findings suggest that outpatient management during neutropenia was a viable approach without excess risk for many patients and was preferred by some families.

 

Read Full Text Here

  CPeRT members develop real-world evidence about the health effects of medications and other medical products, and prepare the next generation of pharmacoepidemiology leaders. CPeRT is an academic partner to the Food and Drug Administration (FDA)-funded Sentinel Initiative. CPeRT members are also editors of the journal Pharmacoepidemiology and Drug Safety, and the books Pharmacoepidemiology, 6th edition and Textbook of Pharmacoepidemiology, 3rd edition.   

DIRECTIONS TO CPERT

8th Floor, Blockley Hall

University of Pennsylvania

423 Guardian Drive

Philadelphia, PA 19104-6021

 

SOCIAL MEDIA